Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced the formation of its clinical advisory board. Additions to the board include Maurizio Fava, MD, psychiatrist-in-chief in the Department of Psychiatry at Massachusetts General Hospital, Lynn Marie Morski, MD, Esq., president of the Psychedelic Medicine Association, and Anthony Back, MD, professor in the Department of Medicine and Division of Oncology at the University of Washington. Alex Belser, PhD, Cybin’s chief clinical officer, will chair the clinical advisory board. “We are delighted to welcome three accomplished experts in their respective fields to guide the strategic development of Cybin’s clinical programs,” said Doug Drysdale, Cybin’s chief executive officer. “Together, Drs. Fava, Morski and Back add unparalleled clinical expertise and strengthen our position to advance psychedelic therapeutics. Their insights will be especially valuable as we move our development pipeline through clinical trials.”
In addition, Cybin announced that it will present at the Bloom Burton & Co. Health Care Investor Conference. According to the update, CEO Doug Drysdale is scheduled to present at 2 p.m. ET on Wednesday April 21, 2021. Interested parties should visit https://ibn.fm/VzQR7 to register for the event.
About Cybin Inc.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.